{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Yojana Gadiya",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "PERK activation mitigates tau pathology in vitro and in vivo.",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "FMA": "^\\d+$",
      "OMIT": "^\\d{7}$",
      "PUBCHEM": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/cbd60cabbfc644257177ffd3abc7946be0c454e6/export/conso-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "EFO": "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
    },
    "path": "er-stress/bruch2017.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Anatomy": {
          "frontal cortex": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "An increase in phosphorylated PERK (pPERK) was detected in PSP, as previously shown by immunohistochemistry (Nijholt et al, 2012; Stutzbach et al, 2013). Total PERK protein was increased as well.",
      "key": "1937ce37b1af3137c35eae959880b646",
      "line": 89,
      "relation": "increases",
      "source": 68,
      "target": 49
    },
    {
      "annotations": {
        "Anatomy": {
          "frontal cortex": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "An increase in phosphorylated PERK (pPERK) was detected in PSP, as previously shown by immunohistochemistry (Nijholt et al, 2012; Stutzbach et al, 2013). Total PERK protein was increased as well.",
      "key": "8f69fd73fc1c88db2a581b083126df0b",
      "line": 90,
      "relation": "increases",
      "source": 68,
      "target": 48
    },
    {
      "annotations": {
        "Anatomy": {
          "frontal cortex": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Surprisingly, the PERK substrate EIF2A and phosphorylated EIF2A (pEIF2A) were reduced in PSP.",
      "key": "50876c2390e27cb6be56a9d5de839ce2",
      "line": 96,
      "relation": "decreases",
      "source": 68,
      "target": 46
    },
    {
      "annotations": {
        "Anatomy": {
          "frontal cortex": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Surprisingly, the PERK substrate EIF2A and phosphorylated EIF2A (pEIF2A) were reduced in PSP.",
      "key": "0204f00e9437f31d0b718bea581e4484",
      "line": 97,
      "relation": "decreases",
      "source": 68,
      "target": 47
    },
    {
      "annotations": {
        "Anatomy": {
          "frontal cortex": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, the second major PERK substrate, NRF2, was increased with regard to total and phosphorylated protein (pNRF2).",
      "key": "6c078eb2fdc4eb7b43e252f6e7585ebf",
      "line": 104,
      "relation": "increases",
      "source": 68,
      "target": 60
    },
    {
      "annotations": {
        "Anatomy": {
          "frontal cortex": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, the second major PERK substrate, NRF2, was increased with regard to total and phosphorylated protein (pNRF2).",
      "key": "135a92609144f79f02d0666985c027ad",
      "line": 105,
      "relation": "increases",
      "source": 68,
      "target": 61
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Thapsigargin induces UPR stress and served as positive control for PERK and EIF2A phosphorylation (Fig 1C and D).",
      "key": "8536099566d1d678f9bec3eacf97ae42",
      "line": 122,
      "relation": "positiveCorrelation",
      "source": 49,
      "target": 2
    },
    {
      "key": "c945615f0603a36ae7b9f2db4cc02647",
      "relation": "hasVariant",
      "source": 48,
      "target": 49
    },
    {
      "annotations": {
        "Anatomy": {
          "frontal cortex": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, the second major PERK substrate, NRF2, was increased with regard to total and phosphorylated protein (pNRF2).",
      "key": "29bc2fe94b4047f7b07f5408a74676b9",
      "line": 106,
      "relation": "association",
      "source": 48,
      "target": 60
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "PERK overexpression reversed the annonacin-induced increase in 4R MAPT mRNA (Fig EV5B) and protected LUHMES neurons against toxicity induced by annonacin (Fig EV5C and D) and 4R tau overexpression in a similar fashion to PERK activator treatment (Fig EV5E and F).",
      "key": "4d355428aa1ea2ca29415aaea5bf0668",
      "line": 445,
      "relation": "decreases",
      "source": 48,
      "target": 40
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "PERK overexpression reversed the annonacin-induced increase in 4R MAPT mRNA (Fig EV5B) and protected LUHMES neurons against toxicity induced by annonacin (Fig EV5C and D) and 4R tau overexpression in a similar fashion to PERK activator treatment (Fig EV5E and F).",
      "key": "203f2a282aa8a7f14ef41cb511b8489c",
      "line": 446,
      "relation": "decreases",
      "source": 48,
      "target": 28
    },
    {
      "key": "add8d5d7232e28bc4f04e3dd758c202f",
      "relation": "hasVariant",
      "source": 46,
      "target": 47
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Thapsigargin induces UPR stress and served as positive control for PERK and EIF2A phosphorylation (Fig 1C and D).",
      "key": "c43df191503c5bd2041276d69bc32f6e",
      "line": 123,
      "relation": "positiveCorrelation",
      "source": 47,
      "target": 2
    },
    {
      "key": "68974b58dba26e9c0f589d5cf27ae85b",
      "relation": "hasVariant",
      "source": 60,
      "target": 61
    },
    {
      "annotations": {
        "Anatomy": {
          "frontal cortex": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, the second major PERK substrate, NRF2, was increased with regard to total and phosphorylated protein (pNRF2).",
      "key": "943ea066a20097cead98915d308d4194",
      "line": 106,
      "relation": "association",
      "source": 60,
      "target": 48
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "NRF2 regulates several downstream pathways, including iron sequestration controlled by heme oxygenase-1 (HO-1; Gorrini et al, 2013).",
      "key": "41411c4a54a166ad5d5a0f244ceb5ed6",
      "line": 303,
      "relation": "regulates",
      "source": 60,
      "target": 50
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "NRF2 regulates several downstream pathways, including iron sequestration controlled by heme oxygenase-1 (HO-1; Gorrini et al, 2013).",
      "key": "f6b311b0df39d65deb3494143fba2859",
      "line": 305,
      "relation": "regulates",
      "source": 60,
      "target": 19
    },
    {
      "key": "0f93b58dfd6ff2db5509fb6a4615036d",
      "relation": "partOf",
      "source": 60,
      "target": 32
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Thapsigargin induces UPR stress and served as positive control for PERK and EIF2A phosphorylation (Fig 1C and D).",
      "key": "6faf23e02215084b007e1333b2aaeae3",
      "line": 121,
      "relation": "increases",
      "source": 2,
      "target": 22
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Thapsigargin induces UPR stress and served as positive control for PERK and EIF2A phosphorylation (Fig 1C and D).",
      "key": "5ffe08170fd068703d26faf93346113f",
      "line": 122,
      "relation": "positiveCorrelation",
      "source": 2,
      "target": 49
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Thapsigargin induces UPR stress and served as positive control for PERK and EIF2A phosphorylation (Fig 1C and D).",
      "key": "de406077489b41dfdb8f8db196a08649",
      "line": 123,
      "relation": "positiveCorrelation",
      "source": 2,
      "target": 47
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "None of the lentiviral models significantly increased PERK or pPERK, showing that tau overload per se is not sufficient to activate the UPR.",
      "key": "f127d5f174565ab678b1c2d53b5b32fd",
      "line": 178,
      "relation": "association",
      "source": 22,
      "target": 51
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cultured neurons treated with low doses of annonacin exhibit hallmarks of tauopathy, including increased tau concentration, tau hyperphosphorylation, cell death and somatodendritic redistribution of hyperphosphorylated tau in a manner dependent on mitochondrial complex I activity (Lannuzel et al, 2003; Escobar-Khondiker et al, 2007; Yamada et al, 2014).",
      "key": "8049324018dce9c8bc94e903e43bf40f",
      "line": 134,
      "relation": "association",
      "source": 12,
      "target": 69
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cultured neurons treated with low doses of annonacin exhibit hallmarks of tauopathy, including increased tau concentration, tau hyperphosphorylation, cell death and somatodendritic redistribution of hyperphosphorylated tau in a manner dependent on mitochondrial complex I activity (Lannuzel et al, 2003; Escobar-Khondiker et al, 2007; Yamada et al, 2014).",
      "key": "486735e352221bd81cd896281253d51c",
      "line": 135,
      "relation": "increases",
      "source": 12,
      "target": 51
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cultured neurons treated with low doses of annonacin exhibit hallmarks of tauopathy, including increased tau concentration, tau hyperphosphorylation, cell death and somatodendritic redistribution of hyperphosphorylated tau in a manner dependent on mitochondrial complex I activity (Lannuzel et al, 2003; Escobar-Khondiker et al, 2007; Yamada et al, 2014).",
      "key": "ec2768ca4e9e90c640e1b408bb822e88",
      "line": 136,
      "relation": "increases",
      "source": 12,
      "target": 52
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cultured neurons treated with low doses of annonacin exhibit hallmarks of tauopathy, including increased tau concentration, tau hyperphosphorylation, cell death and somatodendritic redistribution of hyperphosphorylated tau in a manner dependent on mitochondrial complex I activity (Lannuzel et al, 2003; Escobar-Khondiker et al, 2007; Yamada et al, 2014).",
      "key": "d4b87dbbf62fd3c427d13649d5b38bd7",
      "line": 140,
      "object": {
        "location": {
          "name": "somatodendritic compartment",
          "namespace": "GO"
        }
      },
      "relation": "increases",
      "source": 12,
      "target": 52
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cultured neurons treated with low doses of annonacin exhibit hallmarks of tauopathy, including increased tau concentration, tau hyperphosphorylation, cell death and somatodendritic redistribution of hyperphosphorylated tau in a manner dependent on mitochondrial complex I activity (Lannuzel et al, 2003; Escobar-Khondiker et al, 2007; Yamada et al, 2014).",
      "key": "f7176dae8effd928d28996de8c185612",
      "line": 137,
      "relation": "increases",
      "source": 12,
      "target": 16
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cultured neurons treated with low doses of annonacin exhibit hallmarks of tauopathy, including increased tau concentration, tau hyperphosphorylation, cell death and somatodendritic redistribution of hyperphosphorylated tau in a manner dependent on mitochondrial complex I activity (Lannuzel et al, 2003; Escobar-Khondiker et al, 2007; Yamada et al, 2014).",
      "key": "abce0cbda844734c422bb13002a1ebf9",
      "line": 138,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 12,
      "target": 62
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin (25 nM for 48 h) increased pPERK, while total PERK and EIF2A were reduced (Fig 1C and D).",
      "key": "71c45e3aebada02fd829f9e77f566f44",
      "line": 148,
      "relation": "increases",
      "source": 12,
      "target": 49
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin (25 nM for 48 h) increased pPERK, while total PERK and EIF2A were reduced (Fig 1C and D).",
      "key": "b8aa4cbcea6d78d9b3dce37771723198",
      "line": 149,
      "relation": "decreases",
      "source": 12,
      "target": 48
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin (25 nM for 48 h) increased pPERK, while total PERK and EIF2A were reduced (Fig 1C and D).",
      "key": "5e40e37ddf9693ec8836caf667c4c01b",
      "line": 150,
      "relation": "decreases",
      "source": 12,
      "target": 46
    },
    {
      "key": "9b22d25f41cc29d8a8db6c84b3b0f326",
      "relation": "partOf",
      "source": 12,
      "target": 26
    },
    {
      "key": "0942ab3a14c0f0ff1954a158e36453d7",
      "relation": "partOf",
      "source": 12,
      "target": 33
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin caused a concentration-dependent decline in both MTT signal and ATP concentration (Fig 2A and B).",
      "key": "e5dfae6c8875913fb34e5f2b16fbda6f",
      "line": 253,
      "relation": "decreases",
      "source": 12,
      "target": 0
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin caused a concentration-dependent decline in both MTT signal and ATP concentration (Fig 2A and B).",
      "key": "faf105be17ca05078720006104a15730",
      "line": 255,
      "relation": "decreases",
      "source": 12,
      "target": 1
    },
    {
      "key": "9c597ab99d833476613a993ecaad805e",
      "relation": "partOf",
      "source": 12,
      "target": 34
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin but not 4R or 3R tau overexpression increased the level of MC1-immunoreactive tau in LUHMES neurons.",
      "key": "ce9eebfffb38ee95cf61ef0bf4ea2b63",
      "line": 333,
      "relation": "increases",
      "source": 12,
      "target": 4
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin also increased phosphorylation of tau on the epitopes Ser-202 (CP13 antibody; Ishizawa et al, 2003) and Ser-396 and Ser- 404 (AD2 antibody; Buee-Scherrer et al, 1996; Fig 3A and B). The PERK activator reduced this effect.",
      "key": "d33d74dbb2fbb38eb2a4d232d899298a",
      "line": 350,
      "relation": "increases",
      "source": 12,
      "target": 43
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin also increased phosphorylation of tau on the epitopes Ser-202 (CP13 antibody; Ishizawa et al, 2003) and Ser-396 and Ser- 404 (AD2 antibody; Buee-Scherrer et al, 1996; Fig 3A and B). The PERK activator reduced this effect.",
      "key": "bd379161e0972fc6d1df16fde239710d",
      "line": 351,
      "relation": "increases",
      "source": 12,
      "target": 54
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin also increased phosphorylation of tau on the epitopes Ser-202 (CP13 antibody; Ishizawa et al, 2003) and Ser-396 and Ser- 404 (AD2 antibody; Buee-Scherrer et al, 1996; Fig 3A and B). The PERK activator reduced this effect.",
      "key": "1baea52392d42b39d055ee531c9422f2",
      "line": 352,
      "relation": "increases",
      "source": 12,
      "target": 55
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin also increased phosphorylation of tau on the epitopes Ser-202 (CP13 antibody; Ishizawa et al, 2003) and Ser-396 and Ser- 404 (AD2 antibody; Buee-Scherrer et al, 1996; Fig 3A and B). The PERK activator reduced this effect.",
      "key": "bffd2dade741c09a21f00cfecfb36290",
      "line": 353,
      "relation": "increases",
      "source": 12,
      "target": 56
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin also increased phosphorylation of tau on the epitopes Ser-202 (CP13 antibody; Ishizawa et al, 2003) and Ser-396 and Ser- 404 (AD2 antibody; Buee-Scherrer et al, 1996; Fig 3A and B). The PERK activator reduced this effect.",
      "key": "c24db6d7c28099b4f0f15bdf4424fce5",
      "line": 354,
      "relation": "increases",
      "source": 12,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Total tau protein (HT7 antibody) was not altered by treatment with annonacin or the PERK activator (Fig 3A and D).",
      "key": "a75915df1a5391bf834bc1d7335d691f",
      "line": 367,
      "relation": "causesNoChange",
      "source": 12,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Consistent with previous work (Bruch et al, 2014), annonacin increased 4R tau, but not 3R tau levels, both at the protein and mRNA level (Fig 3A, D and E). The PERK activator reduced the amount of 4R tau mRNA and protein, and almost completely reversed the effect of annonacin on the 3R/4R ratio (Fig 3A, D and E).",
      "key": "38aa820455aae1d9fd473953dfd5022c",
      "line": 378,
      "relation": "increases",
      "source": 12,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Consistent with previous work (Bruch et al, 2014), annonacin increased 4R tau, but not 3R tau levels, both at the protein and mRNA level (Fig 3A, D and E). The PERK activator reduced the amount of 4R tau mRNA and protein, and almost completely reversed the effect of annonacin on the 3R/4R ratio (Fig 3A, D and E).",
      "key": "b7b2f44f7d6a4b800cdb9aec15bd8c02",
      "line": 379,
      "relation": "causesNoChange",
      "source": 12,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "In the presence of annonacin, mRNA levels of the tau splicing factor SRSF2 increased (Fig 3F). Interestingly, the PERK activator blocked this effect.",
      "key": "4eba0781e1131029eb4bb85a0490505e",
      "line": 387,
      "relation": "increases",
      "source": 12,
      "target": 75
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Western blots of LUHMES neurons treated with annonacin and the PERK activator showed that phosphorylated NFM was decreased by annonacin and the decline was prevented by PERK activator (Appendix Fig S2A and B).",
      "key": "269de3a4f284303f1b09ef60d1e05229",
      "line": 426,
      "relation": "decreases",
      "source": 12,
      "target": 59
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "This suggests that axonal pathology induced by annonacin-treated cells was associated with dephosphorylation of NFL and prevented by PERK activator treatment.",
      "key": "5022d03cdd88ba8ec7de528292a7d3d0",
      "line": 434,
      "relation": "increases",
      "source": 12,
      "target": 67
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cultured neurons treated with low doses of annonacin exhibit hallmarks of tauopathy, including increased tau concentration, tau hyperphosphorylation, cell death and somatodendritic redistribution of hyperphosphorylated tau in a manner dependent on mitochondrial complex I activity (Lannuzel et al, 2003; Escobar-Khondiker et al, 2007; Yamada et al, 2014).",
      "key": "ee6909d0c24a1076681832fe9e2463ec",
      "line": 134,
      "relation": "association",
      "source": 69,
      "target": 12
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Neurofilaments are cytoskeletal proteins in axons. Their phosphorylation is essential for axonal functions. Dephosphorylation of the neurofilament medium polypeptide (NFM) impairs axonal calibers (Save et al, 2004). Abnormal phosphorylation of neurofilaments has also been associated with tauopathy (Roher et al, 2013).",
      "key": "480c6d345696e25a6402813a04159ce1",
      "line": 416,
      "relation": "association",
      "source": 69,
      "target": 64
    },
    {
      "key": "b5ef526ab5a17da51fd96bb875e02aac",
      "relation": "hasVariant",
      "source": 51,
      "target": 52
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "None of the lentiviral models significantly increased PERK or pPERK, showing that tau overload per se is not sufficient to activate the UPR.",
      "key": "043778615c64fd2cdd33df8a832d90a9",
      "line": 178,
      "relation": "association",
      "source": 51,
      "target": 22
    },
    {
      "key": "9ee05aee061d4b4c53705f68b8e94026",
      "relation": "hasVariant",
      "source": 51,
      "target": 57
    },
    {
      "key": "0e0ec3a09e8df8d002dd41b58ef30e38",
      "relation": "hasVariant",
      "source": 51,
      "target": 54
    },
    {
      "key": "deebc6415a1d74c0501fe5fae6165d64",
      "relation": "hasVariant",
      "source": 51,
      "target": 55
    },
    {
      "key": "e9808fec4b7de2906ee3a9ab9d1ef29e",
      "relation": "hasVariant",
      "source": 51,
      "target": 56
    },
    {
      "key": "b6fa2321c5ef02894476a04a5375a2bf",
      "relation": "hasVariant",
      "source": 51,
      "target": 53
    },
    {
      "key": "ac1dd67745fccaa0bf7eb3e16ad93cb2",
      "relation": "partOf",
      "source": 51,
      "target": 35
    },
    {
      "key": "04f654b599d96649366266576ec8ea15",
      "relation": "partOf",
      "source": 51,
      "target": 30
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cultured neurons treated with low doses of annonacin exhibit hallmarks of tauopathy, including increased tau concentration, tau hyperphosphorylation, cell death and somatodendritic redistribution of hyperphosphorylated tau in a manner dependent on mitochondrial complex I activity (Lannuzel et al, 2003; Escobar-Khondiker et al, 2007; Yamada et al, 2014).",
      "key": "d6d8f606f601adf3de7b74d44f6ef519",
      "line": 139,
      "object": {
        "location": {
          "name": "somatodendritic compartment",
          "namespace": "GO"
        }
      },
      "relation": "increases",
      "source": 62,
      "subject": {
        "modifier": "Activity"
      },
      "target": 52
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The 2N4R tau encoding virus increased 4R tau mRNA from 80 +/- 10 (control) to 5,000 +/- 2,000 copies/ng total mRNA; the 2N3R tau-encoding virus increased 3R tau mRNA from 1,800 +/- 700 to 7,600 +/- 300 copies/ ng total mRNA; the specific increase of 4R and 3R tau protein was confirmed by Western blot (Appendix Fig S1A and B).",
      "key": "8a9dcd752c9736239197804aa0eacebf",
      "line": 162,
      "relation": "directlyIncreases",
      "source": 45,
      "target": 40
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "None of the lentiviral models significantly increased PERK or pPERK, showing that tau overload per se is not sufficient to activate the UPR.",
      "key": "d1bae69017ecd55389a2330e98d7c5ad",
      "line": 172,
      "relation": "causesNoChange",
      "source": 45,
      "target": 48
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "None of the lentiviral models significantly increased PERK or pPERK, showing that tau overload per se is not sufficient to activate the UPR.",
      "key": "2de7f25c60de08eeb1b3f6ecae45fffa",
      "line": 173,
      "relation": "causesNoChange",
      "source": 45,
      "target": 49
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, similar to the situation in PSP, 4R tau (but not 3R tau or mCherry) suppressed EIF2A at the protein level. pEIF2A was reduced by both 4R and 3R tau.",
      "key": "eb7adf9f1737010256fa5f889bf7be3e",
      "line": 186,
      "relation": "decreases",
      "source": 45,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cells transduced with 4R tau-overexpressing lentivirus showed increased levels in CP13-, AD2-, and HT7 tau (but not MC1). CP13- but not AD2- and HT7 tau were normalized by simultaneous PERK activator treatment (Fig 3G and H).",
      "key": "3d389b2f102ce23666b725c5039f850d",
      "line": 396,
      "relation": "increases",
      "source": 45,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cells transduced with 4R tau-overexpressing lentivirus showed increased levels in CP13-, AD2-, and HT7 tau (but not MC1). CP13- but not AD2- and HT7 tau were normalized by simultaneous PERK activator treatment (Fig 3G and H).",
      "key": "e7ffabc3eea011c36cc529e914de2685",
      "line": 397,
      "relation": "increases",
      "source": 45,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cells transduced with 4R tau-overexpressing lentivirus showed increased levels in CP13-, AD2-, and HT7 tau (but not MC1). CP13- but not AD2- and HT7 tau were normalized by simultaneous PERK activator treatment (Fig 3G and H).",
      "key": "183d77b6b7b06db5fa8ed8cca497e09f",
      "line": 398,
      "relation": "increases",
      "source": 45,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cells transduced with 4R tau-overexpressing lentivirus showed increased levels in CP13-, AD2-, and HT7 tau (but not MC1). CP13- but not AD2- and HT7 tau were normalized by simultaneous PERK activator treatment (Fig 3G and H).",
      "key": "a25701a8085a2463441bb71e8b1c9f44",
      "line": 399,
      "relation": "causesNoChange",
      "source": 45,
      "target": 4
    },
    {
      "key": "241af3dbd301539aacd44e11091b6ee9",
      "relation": "partOf",
      "source": 45,
      "target": 29
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, similar to the situation in PSP, 4R tau (but not 3R tau or mCherry) suppressed EIF2A at the protein level. pEIF2A was reduced by both 4R and 3R tau.",
      "key": "897224cf4cf7e954c87b8bee2a51897b",
      "line": 189,
      "relation": "decreases",
      "source": 40,
      "target": 47
    },
    {
      "key": "e5e0fc98223def9e60a6d48b09d59144",
      "relation": "partOf",
      "source": 40,
      "target": 28
    },
    {
      "key": "fcefa398eadb6a249de753c4ed1b1781",
      "relation": "partOf",
      "source": 40,
      "target": 38
    },
    {
      "key": "1cfa52a2acb593a0f41957d56407524c",
      "relation": "partOf",
      "source": 40,
      "target": 34
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin but not 4R or 3R tau overexpression increased the level of MC1-immunoreactive tau in LUHMES neurons.",
      "key": "561a28233d7a6fe383f39ef65e146733",
      "line": 334,
      "relation": "causesNoChange",
      "source": 40,
      "target": 4
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The 2N4R tau encoding virus increased 4R tau mRNA from 80 +/- 10 (control) to 5,000 +/- 2,000 copies/ng total mRNA; the 2N3R tau-encoding virus increased 3R tau mRNA from 1,800 +/- 700 to 7,600 +/- 300 copies/ ng total mRNA; the specific increase of 4R and 3R tau protein was confirmed by Western blot (Appendix Fig S1A and B).",
      "key": "ecaf009f7a243b8f6e252885f9a15c45",
      "line": 163,
      "relation": "directlyIncreases",
      "source": 44,
      "target": 39
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "None of the lentiviral models significantly increased PERK or pPERK, showing that tau overload per se is not sufficient to activate the UPR.",
      "key": "3a1b999038d330673c23ea2a5f426e6f",
      "line": 174,
      "relation": "causesNoChange",
      "source": 44,
      "target": 48
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "None of the lentiviral models significantly increased PERK or pPERK, showing that tau overload per se is not sufficient to activate the UPR.",
      "key": "0265954a15c39bcd9f696dc3da669576",
      "line": 175,
      "relation": "causesNoChange",
      "source": 44,
      "target": 49
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, similar to the situation in PSP, 4R tau (but not 3R tau or mCherry) suppressed EIF2A at the protein level. pEIF2A was reduced by both 4R and 3R tau.",
      "key": "9e75529f7e1636f6e4baf1f446f522ad",
      "line": 187,
      "relation": "causesNoChange",
      "source": 44,
      "target": 46
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, similar to the situation in PSP, 4R tau (but not 3R tau or mCherry) suppressed EIF2A at the protein level. pEIF2A was reduced by both 4R and 3R tau.",
      "key": "c151f182385ca92e333cad9f94b9720e",
      "line": 190,
      "relation": "decreases",
      "source": 39,
      "target": 47
    },
    {
      "key": "5dc78ddf4ac0bf6e23e56664f0b900a4",
      "relation": "partOf",
      "source": 39,
      "target": 27
    },
    {
      "key": "b20f9f254c45cb8e79d3d22169b38719",
      "relation": "partOf",
      "source": 39,
      "target": 37
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin but not 4R or 3R tau overexpression increased the level of MC1-immunoreactive tau in LUHMES neurons.",
      "key": "b8ed7af48847e15307a75b4f12878b9b",
      "line": 335,
      "relation": "causesNoChange",
      "source": 39,
      "target": 4
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "None of the lentiviral models significantly increased PERK or pPERK, showing that tau overload per se is not sufficient to activate the UPR.",
      "key": "ac386aa2bf3d327b70c10899d46aeffa",
      "line": 176,
      "relation": "causesNoChange",
      "source": 65,
      "target": 48
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "None of the lentiviral models significantly increased PERK or pPERK, showing that tau overload per se is not sufficient to activate the UPR.",
      "key": "ef8a45f06da3af55d975e0a16daf00e0",
      "line": 177,
      "relation": "causesNoChange",
      "source": 65,
      "target": 49
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, similar to the situation in PSP, 4R tau (but not 3R tau or mCherry) suppressed EIF2A at the protein level. pEIF2A was reduced by both 4R and 3R tau.",
      "key": "ef75ad5fd3694d3efdca198787c05c10",
      "line": 188,
      "relation": "causesNoChange",
      "source": 65,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Indeed, pEIF2A was downregulated in 2- and 6-month-old mice, but PERK, pPERK, and pNRF2 were only increased in 6-month but not in 2-month-old mice.",
      "key": "a982e20a31ff30e8a7a1e539d521a8ea",
      "line": 201,
      "relation": "decreases",
      "source": 57,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Indeed, pEIF2A was downregulated in 2- and 6-month-old mice, but PERK, pPERK, and pNRF2 were only increased in 6-month but not in 2-month-old mice.",
      "key": "0b412f98356cf4a002ace3ad2188259a",
      "line": 203,
      "relation": "increases",
      "source": 57,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Indeed, pEIF2A was downregulated in 2- and 6-month-old mice, but PERK, pPERK, and pNRF2 were only increased in 6-month but not in 2-month-old mice.",
      "key": "e44db7c9ed282ff965a1b2d66223e097",
      "line": 204,
      "relation": "increases",
      "source": 57,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Indeed, pEIF2A was downregulated in 2- and 6-month-old mice, but PERK, pPERK, and pNRF2 were only increased in 6-month but not in 2-month-old mice.",
      "key": "557fc4bdd573db9cb6733a2ef6635a82",
      "line": 205,
      "relation": "increases",
      "source": 57,
      "target": 61
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "37fa77566e7ea15fd8de0beaabb4c498",
      "line": 462,
      "relation": "increases",
      "source": 57,
      "target": 70
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "abe27c824f37fb54dd8dfba4b2753fd1",
      "line": 463,
      "relation": "increases",
      "source": 57,
      "target": 53
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "1e7bcc474d80c149aa36781a11ede6f9",
      "line": 464,
      "relation": "negativeCorrelation",
      "source": 57,
      "target": 72
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "71bf8766ad7bc84ca80261d264f13d68",
      "line": 466,
      "relation": "negativeCorrelation",
      "source": 57,
      "target": 18
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "151969b93d10a7dca9ee9e5d60edf093",
      "line": 469,
      "relation": "negativeCorrelation",
      "source": 57,
      "target": 73
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "a0ca3a9f77ec4391aa3e2778edaa3c3f",
      "line": 470,
      "relation": "increases",
      "source": 57,
      "target": 5
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "6f6fc4c067e5e16049a4680ff083b5e2",
      "line": 471,
      "relation": "negativeCorrelation",
      "source": 57,
      "target": 6
    },
    {
      "key": "35a79729ff2ec5b7d4111b7f3aacccca",
      "relation": "partOf",
      "source": 57,
      "target": 31
    },
    {
      "key": "1df4d60550711eaf8542b911a3057d92",
      "relation": "partOf",
      "source": 57,
      "target": 36
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Consistent with prior studies (Allen et al, 2002; Scattoni et al, 2010), we found swollen and atrophic motoneurons and reduced numbers of intact motoneurons in P301S mice (Fig 5E and F). There was a loss of adductor and quadriceps motoneurons of lamina 9 (Ad9) and lamina Q9, and PERK activator treatment prevented this loss (Fig 5E and F).",
      "key": "b7e744990e60da8bd983fc526b851209",
      "line": 539,
      "relation": "negativeCorrelation",
      "source": 57,
      "target": 7
    },
    {
      "annotations": {
        "Anatomy": {
          "adductor magnus": true,
          "biceps femoris": true
        },
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Consistent with prior studies (Allen et al, 2002; Scattoni et al, 2010), we found swollen and atrophic motoneurons and reduced numbers of intact motoneurons in P301S mice (Fig 5E and F). There was a loss of adductor and quadriceps motoneurons of lamina 9 (Ad9) and lamina Q9, and PERK activator treatment prevented this loss (Fig 5E and F).",
      "key": "1bcaddaee0dafa97ae14000e071db540",
      "line": 541,
      "relation": "negativeCorrelation",
      "source": 57,
      "target": 8
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "In the presence of annonacin (Fig EV2D and E), the PERK activator increased pNRF2, but not pEIF2A; the PERK inhibitor reduced pEIF2A levels significantly.",
      "key": "a0c4d5e11f69b19f88124534537e00d5",
      "line": 223,
      "relation": "increases",
      "source": 11,
      "target": 48
    },
    {
      "key": "f224217343f72ac280c288ffa607a262",
      "relation": "partOf",
      "source": 11,
      "target": 26
    },
    {
      "key": "065d2d95d7f552705a4d4194d5d08b2f",
      "relation": "partOf",
      "source": 11,
      "target": 28
    },
    {
      "key": "f6176bc30fc6c9edbb795e84ea1628fa",
      "relation": "partOf",
      "source": 11,
      "target": 27
    },
    {
      "key": "d89dc96a016ae0618caaa2f313b2e2ee",
      "relation": "partOf",
      "source": 11,
      "target": 23
    },
    {
      "key": "b6855b966df633d8f95a260ab108d4c4",
      "relation": "partOf",
      "source": 11,
      "target": 24
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin and 4R tau overexpression caused chromatin clumps (Fig 2E) and reduced the density of the neuritic network (Fig 2F; quantified in Fig EV3). Counts of viable cells (Fig 2G) confirmed that the PERK activator mitigated the toxicity of both annonacin and 4R tau overexpression.",
      "key": "7c589a6ca2fe8ab42311bb288f409bb2",
      "line": 294,
      "relation": "decreases",
      "source": 11,
      "target": 34
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin and 4R tau overexpression caused chromatin clumps (Fig 2E) and reduced the density of the neuritic network (Fig 2F; quantified in Fig EV3). Counts of viable cells (Fig 2G) confirmed that the PERK activator mitigated the toxicity of both annonacin and 4R tau overexpression.",
      "key": "d7c1f0b671bc9c040a3b364c48ca27cd",
      "line": 295,
      "relation": "increases",
      "source": 11,
      "target": 17
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin and 4R tau overexpression caused chromatin clumps (Fig 2E) and reduced the density of the neuritic network (Fig 2F; quantified in Fig EV3). Counts of viable cells (Fig 2G) confirmed that the PERK activator mitigated the toxicity of both annonacin and 4R tau overexpression.",
      "key": "65080d56fcd64bf4edd25edd7952fffc",
      "line": 296,
      "relation": "decreases",
      "source": 11,
      "target": 71
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "We found a significant increase in HO-1 expression in neurons treated with the PERK activator (Fig EV4A and B), which indicates an activation of the PERK–NRF2 pathway.",
      "key": "27a6242c45182738cd0fa28ece650f6c",
      "line": 313,
      "relation": "increases",
      "source": 11,
      "target": 74
    },
    {
      "key": "dce02453e0fc8bc7139e863c974b1c87",
      "relation": "partOf",
      "source": 11,
      "target": 32
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "We found a significant increase in HO-1 expression in neurons treated with the PERK activator (Fig EV4A and B), which indicates an activation of the PERK–NRF2 pathway.",
      "key": "e3366f5c148f98579d34a52f734b25a8",
      "line": 314,
      "relation": "increases",
      "source": 11,
      "target": 32
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "This effect was reversed by PERK activator treatment (Fig 3A and B) and was confirmed on dot blots with non-denatured proteins (Fig 3C).",
      "key": "18ceb891cf274e7fe957ead702020953",
      "line": 342,
      "relation": "decreases",
      "source": 11,
      "target": 4
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin also increased phosphorylation of tau on the epitopes Ser-202 (CP13 antibody; Ishizawa et al, 2003) and Ser-396 and Ser- 404 (AD2 antibody; Buee-Scherrer et al, 1996; Fig 3A and B). The PERK activator reduced this effect.",
      "key": "b6804bfe574452188c2e80a215ac652e",
      "line": 355,
      "relation": "decreases",
      "source": 11,
      "target": 43
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin also increased phosphorylation of tau on the epitopes Ser-202 (CP13 antibody; Ishizawa et al, 2003) and Ser-396 and Ser- 404 (AD2 antibody; Buee-Scherrer et al, 1996; Fig 3A and B). The PERK activator reduced this effect.",
      "key": "eb09e74bed210148f9af4953d8024fba",
      "line": 356,
      "relation": "decreases",
      "source": 11,
      "target": 55
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin also increased phosphorylation of tau on the epitopes Ser-202 (CP13 antibody; Ishizawa et al, 2003) and Ser-396 and Ser- 404 (AD2 antibody; Buee-Scherrer et al, 1996; Fig 3A and B). The PERK activator reduced this effect.",
      "key": "79582337bc3ef5452bb26997974a8026",
      "line": 357,
      "relation": "decreases",
      "source": 11,
      "target": 41
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin also increased phosphorylation of tau on the epitopes Ser-202 (CP13 antibody; Ishizawa et al, 2003) and Ser-396 and Ser- 404 (AD2 antibody; Buee-Scherrer et al, 1996; Fig 3A and B). The PERK activator reduced this effect.",
      "key": "c2a907fb5695c87c8db017e10a637227",
      "line": 358,
      "relation": "decreases",
      "source": 11,
      "target": 54
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin also increased phosphorylation of tau on the epitopes Ser-202 (CP13 antibody; Ishizawa et al, 2003) and Ser-396 and Ser- 404 (AD2 antibody; Buee-Scherrer et al, 1996; Fig 3A and B). The PERK activator reduced this effect.",
      "key": "25aa97299abcc30faa8444fdbd65ec76",
      "line": 359,
      "relation": "decreases",
      "source": 11,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Total tau protein (HT7 antibody) was not altered by treatment with annonacin or the PERK activator (Fig 3A and D).",
      "key": "37e48bfe698a064480d998df0f31714c",
      "line": 368,
      "relation": "causesNoChange",
      "source": 11,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Consistent with previous work (Bruch et al, 2014), annonacin increased 4R tau, but not 3R tau levels, both at the protein and mRNA level (Fig 3A, D and E). The PERK activator reduced the amount of 4R tau mRNA and protein, and almost completely reversed the effect of annonacin on the 3R/4R ratio (Fig 3A, D and E).",
      "key": "e3dcf51e91c2e9fdd24161593cbac2e8",
      "line": 380,
      "relation": "decreases",
      "source": 11,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "In the presence of annonacin, mRNA levels of the tau splicing factor SRSF2 increased (Fig 3F). Interestingly, the PERK activator blocked this effect.",
      "key": "2f34dab0de8fd35f39f1370277eb2ced",
      "line": 388,
      "relation": "directlyDecreases",
      "source": 11,
      "target": 75
    },
    {
      "key": "905ca86049b2315793f563c0a424f452",
      "relation": "partOf",
      "source": 11,
      "target": 29
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Western blots of LUHMES neurons treated with annonacin and the PERK activator showed that phosphorylated NFM was decreased by annonacin and the decline was prevented by PERK activator (Appendix Fig S2A and B).",
      "key": "868a7f7f75716431644106c55aa22e3f",
      "line": 427,
      "relation": "increases",
      "source": 11,
      "target": 59
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "This suggests that axonal pathology induced by annonacin-treated cells was associated with dephosphorylation of NFL and prevented by PERK activator treatment.",
      "key": "8e5a1670b2678c0200080c7de786f8ca",
      "line": 436,
      "relation": "decreases",
      "source": 11,
      "target": 67
    },
    {
      "key": "a421d1afed3ae42809a0a689df7c7212",
      "relation": "partOf",
      "source": 11,
      "target": 31
    },
    {
      "key": "cef9d250b620505ff1d1bfb0d0f56257",
      "relation": "partOf",
      "source": 11,
      "target": 30
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "In the presence of annonacin (Fig EV2D and E), the PERK activator increased pNRF2, but not pEIF2A; the PERK inhibitor reduced pEIF2A levels significantly.",
      "key": "9630814c4deba375c62492659cac1729",
      "line": 224,
      "relation": "increases",
      "source": 26,
      "target": 61
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "In the presence of annonacin (Fig EV2D and E), the PERK activator increased pNRF2, but not pEIF2A; the PERK inhibitor reduced pEIF2A levels significantly.",
      "key": "aa54f6b8958c3ec10e2a996ce6346484",
      "line": 225,
      "relation": "causesNoChange",
      "source": 26,
      "target": 47
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, the PERK activator improved both metabolic activity and ATP concentrations over a broad range of annonacin concentrations.",
      "key": "75cbde9c944b8fe3a12d05708effe686",
      "line": 272,
      "relation": "increases",
      "source": 26,
      "target": 0
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, the PERK activator improved both metabolic activity and ATP concentrations over a broad range of annonacin concentrations.",
      "key": "4261f36fe65ccb5220811063486b5ab8",
      "line": 273,
      "relation": "increases",
      "source": 26,
      "target": 1
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "However, the PERK activator improved both metabolic activity and ATP concentrations over a broad range of annonacin concentrations.",
      "key": "e875a7550d357cbdaef1333d1a5d9070",
      "line": 274,
      "relation": "increases",
      "source": 26,
      "target": 21
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "In the presence of annonacin (Fig EV2D and E), the PERK activator increased pNRF2, but not pEIF2A; the PERK inhibitor reduced pEIF2A levels significantly.",
      "key": "c0722cb7871c06c5b266fb89badd82a8",
      "line": 226,
      "relation": "decreases",
      "source": 14,
      "target": 48
    },
    {
      "key": "b76eace21155e65cc6bb07d609621742",
      "relation": "partOf",
      "source": 14,
      "target": 33
    },
    {
      "key": "316d542db6f5932e866677fdeeb53ad6",
      "relation": "partOf",
      "source": 14,
      "target": 38
    },
    {
      "key": "e287ff1d63b5a4fcdbe1deb3809f3206",
      "relation": "partOf",
      "source": 14,
      "target": 37
    },
    {
      "key": "ddef7913af2d4b077a72a11a44af5470",
      "relation": "partOf",
      "source": 14,
      "target": 25
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "In the presence of annonacin (Fig EV2D and E), the PERK activator increased pNRF2, but not pEIF2A; the PERK inhibitor reduced pEIF2A levels significantly.",
      "key": "272e926a2884bb914ffbfff2a6dad9be",
      "line": 227,
      "relation": "decreases",
      "source": 33,
      "target": 47
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Co-treatment with the PERK inhibitor did not improve the cell metabolic activity (MTT signal). Only ATP concentrations improved at the lowest annonacin concentration (12.5 nM).",
      "key": "0763c5e001e483f41362a3f015648925",
      "line": 263,
      "relation": "causesNoChange",
      "source": 33,
      "target": 0
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Co-treatment with the PERK inhibitor did not improve the cell metabolic activity (MTT signal). Only ATP concentrations improved at the lowest annonacin concentration (12.5 nM).",
      "key": "ba0411c954f556576ea485320b82ea33",
      "line": 265,
      "relation": "increases",
      "source": 33,
      "target": 1
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "When overexpressing 4R tau in neurons, PERK activator treatment still increased pNRF2, but not pEIF2A (Fig EV2F and G), while PERK inhibitor treatment decreased pEIF2A but not pNRF2.",
      "key": "c708f7422d83db5dfc4304e0b260f838",
      "line": 234,
      "relation": "increases",
      "source": 28,
      "target": 61
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "When overexpressing 4R tau in neurons, PERK activator treatment still increased pNRF2, but not pEIF2A (Fig EV2F and G), while PERK inhibitor treatment decreased pEIF2A but not pNRF2.",
      "key": "02b7c2dab4182569f053c9d431ce54b7",
      "line": 235,
      "relation": "causesNoChange",
      "source": 28,
      "target": 47
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "When overexpressing 4R tau in neurons, PERK activator treatment still increased pNRF2, but not pEIF2A (Fig EV2F and G), while PERK inhibitor treatment decreased pEIF2A but not pNRF2.",
      "key": "b8c3ac0f859165162f14f5efe901ea9d",
      "line": 236,
      "relation": "decreases",
      "source": 38,
      "target": 47
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "When overexpressing 4R tau in neurons, PERK activator treatment still increased pNRF2, but not pEIF2A (Fig EV2F and G), while PERK inhibitor treatment decreased pEIF2A but not pNRF2.",
      "key": "02a6dfc3d153e357342c7cf080197843",
      "line": 237,
      "relation": "causesNoChange",
      "source": 38,
      "target": 61
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Upon 3R tau overexpression, PERK modulation showed no significant changes",
      "key": "dd400e39daed582d77c1f6e1ac25d5cd",
      "line": 243,
      "relation": "causesNoChange",
      "source": 27,
      "target": 47
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Upon 3R tau overexpression, PERK modulation showed no significant changes",
      "key": "fa36e8fcbaa156df9c126b7cd6f363a4",
      "line": 244,
      "relation": "causesNoChange",
      "source": 27,
      "target": 61
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Upon 3R tau overexpression, PERK modulation showed no significant changes",
      "key": "93278d1473a47a043bfca7bd5e8112f8",
      "line": 245,
      "relation": "causesNoChange",
      "source": 37,
      "target": 47
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Upon 3R tau overexpression, PERK modulation showed no significant changes",
      "key": "53434f090e58222ddf962add491189da",
      "line": 246,
      "relation": "causesNoChange",
      "source": 37,
      "target": 61
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin caused a concentration-dependent decline in both MTT signal and ATP concentration (Fig 2A and B).",
      "key": "fa246be4ec393232015363dd7e4941ce",
      "line": 254,
      "relation": "association",
      "source": 0,
      "target": 21
    },
    {
      "key": "e8768b676165caffabee8c89ca080d88",
      "relation": "partOf",
      "source": 0,
      "target": 23
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin caused a concentration-dependent decline in both MTT signal and ATP concentration (Fig 2A and B).",
      "key": "3599bf4b49a79e07287ea18a95864433",
      "line": 254,
      "relation": "association",
      "source": 21,
      "target": 0
    },
    {
      "key": "27d4ea3193ef09695845831b0cd3a359",
      "relation": "partOf",
      "source": 1,
      "target": 24
    },
    {
      "key": "c084b68c3b1fcc155988fa0f5bb295ec",
      "relation": "partOf",
      "source": 1,
      "target": 25
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The PERK activator reduced 4R tau toxicity as determined in MTT and ATP assays. The PERK inhibitor was slightly protective in the ATP assay only.",
      "key": "4593467b4f8503c5462a7cfc08ce7739",
      "line": 281,
      "relation": "decreases",
      "source": 23,
      "target": 66
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The PERK activator reduced 4R tau toxicity as determined in MTT and ATP assays. The PERK inhibitor was slightly protective in the ATP assay only.",
      "key": "ba0837c8099ff9b8fa2b96e7ccf85573",
      "line": 282,
      "relation": "decreases",
      "source": 24,
      "target": 66
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The PERK activator reduced 4R tau toxicity as determined in MTT and ATP assays. The PERK inhibitor was slightly protective in the ATP assay only.",
      "key": "a501783232b71d2bd548af1db2d52e50",
      "line": 283,
      "relation": "decreases",
      "source": 25,
      "target": 66
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin and 4R tau overexpression caused chromatin clumps (Fig 2E) and reduced the density of the neuritic network (Fig 2F; quantified in Fig EV3). Counts of viable cells (Fig 2G) confirmed that the PERK activator mitigated the toxicity of both annonacin and 4R tau overexpression.",
      "key": "ecce45ae4cc6559af00b2138da9c3725",
      "line": 292,
      "relation": "negativeCorrelation",
      "source": 34,
      "target": 17
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin and 4R tau overexpression caused chromatin clumps (Fig 2E) and reduced the density of the neuritic network (Fig 2F; quantified in Fig EV3). Counts of viable cells (Fig 2G) confirmed that the PERK activator mitigated the toxicity of both annonacin and 4R tau overexpression.",
      "key": "3334be46f80f88d3e1ff10e52ca22bfd",
      "line": 293,
      "relation": "increases",
      "source": 34,
      "target": 71
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Annonacin and 4R tau overexpression caused chromatin clumps (Fig 2E) and reduced the density of the neuritic network (Fig 2F; quantified in Fig EV3). Counts of viable cells (Fig 2G) confirmed that the PERK activator mitigated the toxicity of both annonacin and 4R tau overexpression.",
      "key": "c43c6d35a372527c3225f30037223aa5",
      "line": 292,
      "relation": "negativeCorrelation",
      "source": 17,
      "target": 34
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "NRF2 regulates several downstream pathways, including iron sequestration controlled by heme oxygenase-1 (HO-1; Gorrini et al, 2013).",
      "key": "356319158d04424c4c544eb1456b85e2",
      "line": 304,
      "relation": "regulates",
      "source": 50,
      "target": 19
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Indeed, the toxicity of LV-4R was significantly reduced by treatment with an activator of NRF2 (DL-sulforaphane N-acetyl-L-cysteine; Fig EV4C), and exacerbated by siRNA targeting NFE2L2 (the NRF2 gene; Fig EV4D and Appendix Fig S4; Dinkova-Kostova et al, 2002; Wang et al, 2012).",
      "key": "5f1bda4a827788a3b8b3f532e444cf5d",
      "line": 325,
      "relation": "increases",
      "source": 15,
      "target": 60
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Indeed, the toxicity of LV-4R was significantly reduced by treatment with an activator of NRF2 (DL-sulforaphane N-acetyl-L-cysteine; Fig EV4C), and exacerbated by siRNA targeting NFE2L2 (the NRF2 gene; Fig EV4D and Appendix Fig S4; Dinkova-Kostova et al, 2002; Wang et al, 2012).",
      "key": "9002e99f536656a395d5ad52d0ac1d0d",
      "line": 326,
      "relation": "decreases",
      "source": 15,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cells transduced with 4R tau-overexpressing lentivirus showed increased levels in CP13-, AD2-, and HT7 tau (but not MC1). CP13- but not AD2- and HT7 tau were normalized by simultaneous PERK activator treatment (Fig 3G and H).",
      "key": "c8fe4beb42c0fd390ed6000826468ddf",
      "line": 400,
      "relation": "decreases",
      "source": 29,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cells transduced with 4R tau-overexpressing lentivirus showed increased levels in CP13-, AD2-, and HT7 tau (but not MC1). CP13- but not AD2- and HT7 tau were normalized by simultaneous PERK activator treatment (Fig 3G and H).",
      "key": "1ba6b67f6326c0867774a46cc2327bab",
      "line": 401,
      "relation": "causesNoChange",
      "source": 29,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Cells transduced with 4R tau-overexpressing lentivirus showed increased levels in CP13-, AD2-, and HT7 tau (but not MC1). CP13- but not AD2- and HT7 tau were normalized by simultaneous PERK activator treatment (Fig 3G and H).",
      "key": "4c75089ca0bd0e17ca1e4c87d0689fc9",
      "line": 402,
      "relation": "causesNoChange",
      "source": 29,
      "target": 3
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Neurofilaments are cytoskeletal proteins in axons. Their phosphorylation is essential for axonal functions. Dephosphorylation of the neurofilament medium polypeptide (NFM) impairs axonal calibers (Save et al, 2004). Abnormal phosphorylation of neurofilaments has also been associated with tauopathy (Roher et al, 2013).",
      "key": "207c5dc1b95bf0fde45238faef704c44",
      "line": 415,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 64,
      "subject": {
        "location": {
          "name": "Axons",
          "namespace": "MESH"
        }
      },
      "target": 9
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Neurofilaments are cytoskeletal proteins in axons. Their phosphorylation is essential for axonal functions. Dephosphorylation of the neurofilament medium polypeptide (NFM) impairs axonal calibers (Save et al, 2004). Abnormal phosphorylation of neurofilaments has also been associated with tauopathy (Roher et al, 2013).",
      "key": "8aa6937d58bc19b79d65cde924f94445",
      "line": 416,
      "relation": "association",
      "source": 64,
      "target": 69
    },
    {
      "key": "9cbfe86a64512b901750790839d2bb3d",
      "relation": "hasVariant",
      "source": 63,
      "target": 64
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Neurofilaments are cytoskeletal proteins in axons. Their phosphorylation is essential for axonal functions. Dephosphorylation of the neurofilament medium polypeptide (NFM) impairs axonal calibers (Save et al, 2004). Abnormal phosphorylation of neurofilaments has also been associated with tauopathy (Roher et al, 2013).",
      "key": "d07cce0faad1b4ace0a314ccdada5274",
      "line": 415,
      "object": {
        "location": {
          "name": "Axons",
          "namespace": "MESH"
        }
      },
      "relation": "association",
      "source": 9,
      "subject": {
        "modifier": "Activity"
      },
      "target": 64
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Neurofilaments are cytoskeletal proteins in axons. Their phosphorylation is essential for axonal functions. Dephosphorylation of the neurofilament medium polypeptide (NFM) impairs axonal calibers (Save et al, 2004). Abnormal phosphorylation of neurofilaments has also been associated with tauopathy (Roher et al, 2013).",
      "key": "53986ce38ab3813ee762548f96fa57e1",
      "line": 417,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 59,
      "target": 9
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "This suggests that axonal pathology induced by annonacin-treated cells was associated with dephosphorylation of NFL and prevented by PERK activator treatment.",
      "key": "d8b42e583f91cc1b170cb44777e9bbe5",
      "line": 435,
      "relation": "decreases",
      "source": 59,
      "target": 67
    },
    {
      "key": "fbac5c3e23d9c603e7f601d39fe839f3",
      "relation": "hasVariant",
      "source": 58,
      "target": 59
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "ab8ffed3d1b5dea1273aca73694f5ba5",
      "line": 464,
      "relation": "negativeCorrelation",
      "source": 72,
      "target": 57
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "86855a59fb7bfc42d99db56a59ae17eb",
      "line": 466,
      "relation": "negativeCorrelation",
      "source": 18,
      "target": 57
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "f9584b855a3cc195a6330104ca05fbe0",
      "line": 469,
      "relation": "negativeCorrelation",
      "source": 73,
      "target": 57
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "The mutation at position 301 of the tau protein in this mouse model leads to an early onset memory deficit starting at 10 weeks of age along with the appearance of conformationally changed tau, phosphorylated tau, and dendritic spine loss in the hippocampus. At 20 weeks of age, the mouse develops locomotor deficits correlated with emergence of paired helical filament tau and alpha-motoneuron loss (Xu et al, 2014).",
      "key": "b0f03648d2b2443cc514ffee889ebb9e",
      "line": 471,
      "relation": "negativeCorrelation",
      "source": 6,
      "target": 57
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Western blots of brain extracts showed an increase in both pPERK and pNRF2 at a lowest effective dose of PERK activator being 2 mg/kg/day (Appendix Fig S3A and B).",
      "key": "1fedc5827479687acd034a09a79121dd",
      "line": 479,
      "relation": "increases",
      "source": 31,
      "target": 49
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Western blots of brain extracts showed an increase in both pPERK and pNRF2 at a lowest effective dose of PERK activator being 2 mg/kg/day (Appendix Fig S3A and B).",
      "key": "3692c7a18bf325fc86ed30c2a44c13ed",
      "line": 480,
      "relation": "increases",
      "source": 31,
      "target": 61
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Optical densities of tau-immunostained sections using HT7 (total tau), MC1 (pathological conformation tau), CP13 and AT180 (phospho-tau) antibodies were significantly decreased upon PERK activator treatment. NeuN staining was unchanged, suggesting that treatment was not neurotoxic (Fig 4C and D). A decrease in all tested epitopes of soluble tau was evident by Western blot analysis (Fig 4E and F). Hyperphosphorylated tau species (detected by CP13) were also decreased in the sarkosyl-insoluble tau fraction (Fig 4G).",
      "key": "4ac0e2f9f76605b7a44aab5d4df8a932",
      "line": 493,
      "relation": "decreases",
      "source": 31,
      "target": 3
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Optical densities of tau-immunostained sections using HT7 (total tau), MC1 (pathological conformation tau), CP13 and AT180 (phospho-tau) antibodies were significantly decreased upon PERK activator treatment. NeuN staining was unchanged, suggesting that treatment was not neurotoxic (Fig 4C and D). A decrease in all tested epitopes of soluble tau was evident by Western blot analysis (Fig 4E and F). Hyperphosphorylated tau species (detected by CP13) were also decreased in the sarkosyl-insoluble tau fraction (Fig 4G).",
      "key": "d2ba2275e73ae49ee2dabf5b87859abb",
      "line": 494,
      "relation": "decreases",
      "source": 31,
      "target": 4
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Optical densities of tau-immunostained sections using HT7 (total tau), MC1 (pathological conformation tau), CP13 and AT180 (phospho-tau) antibodies were significantly decreased upon PERK activator treatment. NeuN staining was unchanged, suggesting that treatment was not neurotoxic (Fig 4C and D). A decrease in all tested epitopes of soluble tau was evident by Western blot analysis (Fig 4E and F). Hyperphosphorylated tau species (detected by CP13) were also decreased in the sarkosyl-insoluble tau fraction (Fig 4G).",
      "key": "0ace3d442337215840045f162db657d0",
      "line": 495,
      "relation": "decreases",
      "source": 31,
      "target": 43
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Optical densities of tau-immunostained sections using HT7 (total tau), MC1 (pathological conformation tau), CP13 and AT180 (phospho-tau) antibodies were significantly decreased upon PERK activator treatment. NeuN staining was unchanged, suggesting that treatment was not neurotoxic (Fig 4C and D). A decrease in all tested epitopes of soluble tau was evident by Western blot analysis (Fig 4E and F). Hyperphosphorylated tau species (detected by CP13) were also decreased in the sarkosyl-insoluble tau fraction (Fig 4G).",
      "key": "4cde446b2049a3683350228fde099661",
      "line": 496,
      "relation": "decreases",
      "source": 31,
      "target": 42
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Wild-type mice improved drastically during the 3 days of learning (Fig 5A) while P301S transgenic mice improved less, indicating memory impairment. P301S transgenic mice treated with PERK activator performed significantly better",
      "key": "dc1dc1c271eacebe802a5a9c74307dcf",
      "line": 508,
      "relation": "increases",
      "source": 31,
      "target": 20
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Wild-type mice showed a typical mushroom type of dentritic spines. Their density was reduced in P301S mice. PERK activator treatment restored this deficit partially.",
      "key": "de7a46db8c0ccb3f88bf012918072594",
      "line": 517,
      "relation": "increases",
      "source": 31,
      "target": 18
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "We used the rotarod test to measure the time span until mice fall off a rotating rod. The time span was significantly reduced in saline treated P301S tau mice compared to wild-type mice, and restored upon PERK activator treatment (Fig 5D).",
      "key": "0452f6d3005d165f9b55593fc46baa5c",
      "line": 528,
      "relation": "increases",
      "source": 31,
      "target": 10
    },
    {
      "annotations": {
        "Anatomy": {
          "adductor magnus": true,
          "biceps femoris": true
        },
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Consistent with prior studies (Allen et al, 2002; Scattoni et al, 2010), we found swollen and atrophic motoneurons and reduced numbers of intact motoneurons in P301S mice (Fig 5E and F). There was a loss of adductor and quadriceps motoneurons of lamina 9 (Ad9) and lamina Q9, and PERK activator treatment prevented this loss (Fig 5E and F).",
      "key": "ca33dfc6da0f471aee375bf688f5aea8",
      "line": 542,
      "relation": "positiveCorrelation",
      "source": 31,
      "target": 8
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Wild-type mice improved drastically during the 3 days of learning (Fig 5A) while P301S transgenic mice improved less, indicating memory impairment. P301S transgenic mice treated with PERK activator performed significantly better",
      "key": "eae936cbc94ab519ddd015f718e211de",
      "line": 507,
      "relation": "increases",
      "source": 35,
      "target": 20
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "We used the rotarod test to measure the time span until mice fall off a rotating rod. The time span was significantly reduced in saline treated P301S tau mice compared to wild-type mice, and restored upon PERK activator treatment (Fig 5D).",
      "key": "f0e16e06cb1004785e92ab03aec5b805",
      "line": 526,
      "relation": "increases",
      "source": 35,
      "target": 10
    },
    {
      "key": "1ae81f607e1b0829e7c9a4819cca75c6",
      "relation": "partOf",
      "source": 13,
      "target": 35
    },
    {
      "key": "71971c6ad21db58d5407c541ec13f372",
      "relation": "partOf",
      "source": 13,
      "target": 36
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Wild-type mice showed a typical mushroom type of dentritic spines. Their density was reduced in P301S mice. PERK activator treatment restored this deficit partially.",
      "key": "ff0dc914103b32039f72f86d321b9552",
      "line": 516,
      "relation": "causesNoChange",
      "source": 30,
      "target": 18
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "We used the rotarod test to measure the time span until mice fall off a rotating rod. The time span was significantly reduced in saline treated P301S tau mice compared to wild-type mice, and restored upon PERK activator treatment (Fig 5D).",
      "key": "e1e702fd5b8f4956a34d4900ccf35b7e",
      "line": 527,
      "relation": "decreases",
      "source": 36,
      "target": 10
    },
    {
      "annotations": {
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Consistent with prior studies (Allen et al, 2002; Scattoni et al, 2010), we found swollen and atrophic motoneurons and reduced numbers of intact motoneurons in P301S mice (Fig 5E and F). There was a loss of adductor and quadriceps motoneurons of lamina 9 (Ad9) and lamina Q9, and PERK activator treatment prevented this loss (Fig 5E and F).",
      "key": "58cd7ca921295819728f36f58f645e5e",
      "line": 539,
      "relation": "negativeCorrelation",
      "source": 7,
      "target": 57
    },
    {
      "annotations": {
        "Anatomy": {
          "adductor magnus": true,
          "biceps femoris": true
        },
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Consistent with prior studies (Allen et al, 2002; Scattoni et al, 2010), we found swollen and atrophic motoneurons and reduced numbers of intact motoneurons in P301S mice (Fig 5E and F). There was a loss of adductor and quadriceps motoneurons of lamina 9 (Ad9) and lamina Q9, and PERK activator treatment prevented this loss (Fig 5E and F).",
      "key": "28ba447d3f26e745f0afc0f0efe1ce92",
      "line": 541,
      "relation": "negativeCorrelation",
      "source": 8,
      "target": 57
    },
    {
      "annotations": {
        "Anatomy": {
          "adductor magnus": true,
          "biceps femoris": true
        },
        "Cell": {
          "neuroblast": true
        },
        "CellLine": {
          "immortal human fetal membrane-derived cell line cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Arzberger T",
          "Bruch J",
          "De Andrade A",
          "Höglinger GU",
          "Kuhn PH",
          "Lichtenthaler SF",
          "Müller U",
          "Rösler TW",
          "Winklhofer KF",
          "Xu H"
        ],
        "date": "2017-03-01",
        "db": "PubMed",
        "db_id": "28148553",
        "db_name": "PERK activation mitigates tau pathology <i>in vitro</i> and <i>in vivo</i>.",
        "first": "Bruch J",
        "journal": "EMBO molecular medicine",
        "last": "Höglinger GU",
        "pages": "371-384",
        "volume": "9"
      },
      "evidence": "Consistent with prior studies (Allen et al, 2002; Scattoni et al, 2010), we found swollen and atrophic motoneurons and reduced numbers of intact motoneurons in P301S mice (Fig 5E and F). There was a loss of adductor and quadriceps motoneurons of lamina 9 (Ad9) and lamina Q9, and PERK activator treatment prevented this loss (Fig 5E and F).",
      "key": "853b2b26d7e4d85dff24af6e36066580",
      "line": 542,
      "relation": "positiveCorrelation",
      "source": 8,
      "target": 31
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide\")",
      "concept": {
        "name": "3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "0967153318fe01c894f51b8103fb2193"
    },
    {
      "bel": "a(CHEBI:ATP)",
      "concept": {
        "name": "ATP",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "08c2bd47cf55782389bbaba34887a39c"
    },
    {
      "bel": "a(CHEBI:thapsigargin)",
      "concept": {
        "name": "thapsigargin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "b818dce734618f56caebf0d4267a0ee4"
    },
    {
      "bel": "a(CONSO:\"Tau antibody, HT7\")",
      "concept": {
        "name": "Tau antibody, HT7",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "ead85696fe03925d2f2fa5b3e944803e"
    },
    {
      "bel": "a(CONSO:\"Tau antibody, MC1\")",
      "concept": {
        "name": "Tau antibody, MC1",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "ed78886678c14e0245af79a9db0e0b0a"
    },
    {
      "bel": "a(CONSO:\"paired helical filaments\")",
      "concept": {
        "name": "paired helical filaments",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "cf5d166157778ce378f93f26ae7c2f3c"
    },
    {
      "bel": "a(FMA:83664)",
      "concept": {
        "name": "83664",
        "namespace": "FMA"
      },
      "function": "Abundance",
      "id": "149662edd36192aa55f1a39f7f48a45e"
    },
    {
      "bel": "a(MESH:\"Motor Neurons\")",
      "concept": {
        "name": "Motor Neurons",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "6194857fbeb6a65f65a78cf7e6822e39"
    },
    {
      "bel": "a(MESH:\"Spinal Cord Ventral Horn\")",
      "concept": {
        "name": "Spinal Cord Ventral Horn",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "1d24826e75934c4ceb5747b4b2da863c"
    },
    {
      "bel": "a(MESH:Axons)",
      "concept": {
        "name": "Axons",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "438b15a6e68338bcf5615b067cf5d271"
    },
    {
      "bel": "a(OMIT:0023601)",
      "concept": {
        "name": "0023601",
        "namespace": "OMIT"
      },
      "function": "Abundance",
      "id": "b4ed81a8b67c897c16f90e8be8556d25"
    },
    {
      "bel": "a(PUBCHEM:3108148)",
      "concept": {
        "name": "3108148",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "337bdc8bb7f2c0f0b3ee1b1fa6fbc57d"
    },
    {
      "bel": "a(PUBCHEM:354398)",
      "concept": {
        "name": "354398",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "a2d351b75a92de2ecb1089541bc4cbd1"
    },
    {
      "bel": "a(PUBCHEM:5234)",
      "concept": {
        "name": "5234",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "9d140fb01a18c4e63d44461f2ae30171"
    },
    {
      "bel": "a(PUBCHEM:53469448)",
      "concept": {
        "name": "53469448",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "6efec89cf5a41438f242c90e38b6b092"
    },
    {
      "bel": "a(PUBCHEM:71772353)",
      "concept": {
        "name": "71772353",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "9538c28d87c2d2c75d6f4027e83b7234"
    },
    {
      "bel": "bp(GO:\"cell death\")",
      "concept": {
        "name": "cell death",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "07a2f2734c3682bcb47105485c15b346"
    },
    {
      "bel": "bp(GO:\"chromatin organization\")",
      "concept": {
        "name": "chromatin organization",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "5a0c48f5eb7c14a999c7ed40a889805f"
    },
    {
      "bel": "bp(GO:\"dendritic spine maintenance\")",
      "concept": {
        "name": "dendritic spine maintenance",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "77b552b03fc87fef02acbff32e45d40b"
    },
    {
      "bel": "bp(GO:\"iron ion homeostasis\")",
      "concept": {
        "name": "iron ion homeostasis",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "a18f33e5ac44dfcff0ec09fcccbb2029"
    },
    {
      "bel": "bp(GO:\"learning or memory\")",
      "concept": {
        "name": "learning or memory",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "f7990d886000f2ae69441a960a7d6236"
    },
    {
      "bel": "bp(GO:\"metabolic process\")",
      "concept": {
        "name": "metabolic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "b65c5a22d4d58f4cd22abf2ece484450"
    },
    {
      "bel": "bp(MESH:\"Unfolded Protein Response\")",
      "concept": {
        "name": "Unfolded Protein Response",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "c42671f45252e9c3893c0e324f1d657b"
    },
    {
      "bel": "composite(a(CHEBI:\"3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide\"), a(PUBCHEM:3108148))",
      "function": "Composite",
      "id": "4c1d9d398a12a8f6536084eec33ea5af",
      "members": [
        {
          "bel": "a(CHEBI:\"3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide\")",
          "concept": {
            "name": "3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "0967153318fe01c894f51b8103fb2193"
        },
        {
          "bel": "a(PUBCHEM:3108148)",
          "concept": {
            "name": "3108148",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "337bdc8bb7f2c0f0b3ee1b1fa6fbc57d"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:ATP), a(PUBCHEM:3108148))",
      "function": "Composite",
      "id": "107b783cab9cb9c3428b96542b0706b2",
      "members": [
        {
          "bel": "a(CHEBI:ATP)",
          "concept": {
            "name": "ATP",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "08c2bd47cf55782389bbaba34887a39c"
        },
        {
          "bel": "a(PUBCHEM:3108148)",
          "concept": {
            "name": "3108148",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "337bdc8bb7f2c0f0b3ee1b1fa6fbc57d"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:ATP), a(PUBCHEM:53469448))",
      "function": "Composite",
      "id": "07fa5eda4a78e72b77299d1c1a76f39c",
      "members": [
        {
          "bel": "a(CHEBI:ATP)",
          "concept": {
            "name": "ATP",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "08c2bd47cf55782389bbaba34887a39c"
        },
        {
          "bel": "a(PUBCHEM:53469448)",
          "concept": {
            "name": "53469448",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "6efec89cf5a41438f242c90e38b6b092"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:3108148), a(PUBCHEM:354398))",
      "function": "Composite",
      "id": "fdffb76099a739a0d7c23ef7c7c99ee4",
      "members": [
        {
          "bel": "a(PUBCHEM:3108148)",
          "concept": {
            "name": "3108148",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "337bdc8bb7f2c0f0b3ee1b1fa6fbc57d"
        },
        {
          "bel": "a(PUBCHEM:354398)",
          "concept": {
            "name": "354398",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "a2d351b75a92de2ecb1089541bc4cbd1"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:3108148), p(CONSO:\"3R tau\"))",
      "function": "Composite",
      "id": "03e32679668ead7e7c958dfc992929b7",
      "members": [
        {
          "bel": "a(PUBCHEM:3108148)",
          "concept": {
            "name": "3108148",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "337bdc8bb7f2c0f0b3ee1b1fa6fbc57d"
        },
        {
          "bel": "p(CONSO:\"3R tau\")",
          "concept": {
            "name": "3R tau",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "246e602cb53558e945b03407c219c5e1"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:3108148), p(CONSO:\"4R tau\"))",
      "function": "Composite",
      "id": "9d41c41a97757c2ede5030034aefd373",
      "members": [
        {
          "bel": "a(PUBCHEM:3108148)",
          "concept": {
            "name": "3108148",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "337bdc8bb7f2c0f0b3ee1b1fa6fbc57d"
        },
        {
          "bel": "p(CONSO:\"4R tau\")",
          "concept": {
            "name": "4R tau",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "c5fd156b7c1a309ed11b8dca3e247657"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:3108148), p(CONSO:\"Tau isoform F (441 aa)\"))",
      "function": "Composite",
      "id": "990dbcb595e37caee89714f6c40ce807",
      "members": [
        {
          "bel": "a(PUBCHEM:3108148)",
          "concept": {
            "name": "3108148",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "337bdc8bb7f2c0f0b3ee1b1fa6fbc57d"
        },
        {
          "bel": "p(CONSO:\"Tau isoform F (441 aa)\")",
          "concept": {
            "name": "Tau isoform F (441 aa)",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "83682de7856cc379117e146862b26202"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:3108148), p(HGNC:MAPT))",
      "function": "Composite",
      "id": "3e98e2a7d462c988652870cc8b0009a6",
      "members": [
        {
          "bel": "a(PUBCHEM:3108148)",
          "concept": {
            "name": "3108148",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "337bdc8bb7f2c0f0b3ee1b1fa6fbc57d"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:3108148), p(HGNC:MAPT, var(\"p.Pro301Ser\")))",
      "function": "Composite",
      "id": "75fe82011242cbe500725b4a2df19ba4",
      "members": [
        {
          "bel": "a(PUBCHEM:3108148)",
          "concept": {
            "name": "3108148",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "337bdc8bb7f2c0f0b3ee1b1fa6fbc57d"
        },
        {
          "bel": "p(HGNC:MAPT, var(\"p.Pro301Ser\"))",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "16bd7609a7950095ffbc2f59f0ef6d0f",
          "variants": [
            {
              "hgvs": "p.Pro301Ser",
              "kind": "hgvs"
            }
          ]
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:3108148), p(HGNC:NFE2L2))",
      "function": "Composite",
      "id": "50ca89f2c8346ac935c3f8abbaf5c5ec",
      "members": [
        {
          "bel": "a(PUBCHEM:3108148)",
          "concept": {
            "name": "3108148",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "337bdc8bb7f2c0f0b3ee1b1fa6fbc57d"
        },
        {
          "bel": "p(HGNC:NFE2L2)",
          "concept": {
            "name": "NFE2L2",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7e8941fff5d3be67079854e55d40d075"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:354398), a(PUBCHEM:53469448))",
      "function": "Composite",
      "id": "80509d77181fb8dffe747c538a421440",
      "members": [
        {
          "bel": "a(PUBCHEM:354398)",
          "concept": {
            "name": "354398",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "a2d351b75a92de2ecb1089541bc4cbd1"
        },
        {
          "bel": "a(PUBCHEM:53469448)",
          "concept": {
            "name": "53469448",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "6efec89cf5a41438f242c90e38b6b092"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:354398), p(CONSO:\"4R tau\"))",
      "function": "Composite",
      "id": "160d39dcfa51628af11ee208fec93df6",
      "members": [
        {
          "bel": "a(PUBCHEM:354398)",
          "concept": {
            "name": "354398",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "a2d351b75a92de2ecb1089541bc4cbd1"
        },
        {
          "bel": "p(CONSO:\"4R tau\")",
          "concept": {
            "name": "4R tau",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "c5fd156b7c1a309ed11b8dca3e247657"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:5234), p(HGNC:MAPT))",
      "function": "Composite",
      "id": "fbc093a6ea6071d1082795f8fa8e421e",
      "members": [
        {
          "bel": "a(PUBCHEM:5234)",
          "concept": {
            "name": "5234",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "9d140fb01a18c4e63d44461f2ae30171"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:5234), p(HGNC:MAPT, var(\"p.Pro301Ser\")))",
      "function": "Composite",
      "id": "58ebb7c3548d3a12363accbf0507e469",
      "members": [
        {
          "bel": "a(PUBCHEM:5234)",
          "concept": {
            "name": "5234",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "9d140fb01a18c4e63d44461f2ae30171"
        },
        {
          "bel": "p(HGNC:MAPT, var(\"p.Pro301Ser\"))",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "16bd7609a7950095ffbc2f59f0ef6d0f",
          "variants": [
            {
              "hgvs": "p.Pro301Ser",
              "kind": "hgvs"
            }
          ]
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:53469448), p(CONSO:\"3R tau\"))",
      "function": "Composite",
      "id": "5768d5e2ef5751b06095166c936b7b98",
      "members": [
        {
          "bel": "a(PUBCHEM:53469448)",
          "concept": {
            "name": "53469448",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "6efec89cf5a41438f242c90e38b6b092"
        },
        {
          "bel": "p(CONSO:\"3R tau\")",
          "concept": {
            "name": "3R tau",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "246e602cb53558e945b03407c219c5e1"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:53469448), p(CONSO:\"4R tau\"))",
      "function": "Composite",
      "id": "3cc8d9b49cff714d077f012bf7a68145",
      "members": [
        {
          "bel": "a(PUBCHEM:53469448)",
          "concept": {
            "name": "53469448",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "6efec89cf5a41438f242c90e38b6b092"
        },
        {
          "bel": "p(CONSO:\"4R tau\")",
          "concept": {
            "name": "4R tau",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "c5fd156b7c1a309ed11b8dca3e247657"
        }
      ]
    },
    {
      "bel": "p(CONSO:\"3R tau\")",
      "concept": {
        "name": "3R tau",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "246e602cb53558e945b03407c219c5e1"
    },
    {
      "bel": "p(CONSO:\"4R tau\")",
      "concept": {
        "name": "4R tau",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "c5fd156b7c1a309ed11b8dca3e247657"
    },
    {
      "bel": "p(CONSO:\"Tau epitope, AD2\")",
      "concept": {
        "name": "Tau epitope, AD2",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "275558ff0923e7ec4e1dceef9e0d50e5"
    },
    {
      "bel": "p(CONSO:\"Tau epitope, AT180\")",
      "concept": {
        "name": "Tau epitope, AT180",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "352358f11263a81a1c6a76f09013f32a"
    },
    {
      "bel": "p(CONSO:\"Tau epitope, CP13\")",
      "concept": {
        "name": "Tau epitope, CP13",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "2d261db22a0f4ee2f073fa5356ca3c00"
    },
    {
      "bel": "p(CONSO:\"Tau isoform C (410 aa)\")",
      "concept": {
        "name": "Tau isoform C (410 aa)",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "61588c638bfada70e4025e029924ed34"
    },
    {
      "bel": "p(CONSO:\"Tau isoform F (441 aa)\")",
      "concept": {
        "name": "Tau isoform F (441 aa)",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "83682de7856cc379117e146862b26202"
    },
    {
      "bel": "p(HGNC:EIF2A)",
      "concept": {
        "name": "EIF2A",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "372eed79e4262379d63d1762d021d771"
    },
    {
      "bel": "p(HGNC:EIF2A, pmod(Ph))",
      "concept": {
        "name": "EIF2A",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "26d3a9da8c375e1e21f6e10e5e7541f7",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:EIF2AK3)",
      "concept": {
        "name": "EIF2AK3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "b81e05bdb4a0257b5fc71dbc4d46cd71"
    },
    {
      "bel": "p(HGNC:EIF2AK3, pmod(Ph))",
      "concept": {
        "name": "EIF2AK3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cbb87db81f87566c7d8437462f5ec59c",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:HMOX1)",
      "concept": {
        "name": "HMOX1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d8af6078f1872edbf59623df2a9fa1c2"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(CONSO:hyperphosphorylation))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0d2d8072f03dcdf148e658067d37b9cb",
      "variants": [
        {
          "concept": {
            "name": "hyperphosphorylation",
            "namespace": "CONSO"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph), var(\"p.Pro301Ser\"))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "408c012134f9b0b8692356f511499517",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        },
        {
          "hgvs": "p.Pro301Ser",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 202))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cdcc3b3f116c5db02d04ca383584aef0",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 202
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 396))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d20659abb6d812839958a31e9d5d259b",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 396
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 404))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "c0bfbdd9489341f82d82ce560ba52523",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 404
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, var(\"p.Pro301Ser\"))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "16bd7609a7950095ffbc2f59f0ef6d0f",
      "variants": [
        {
          "hgvs": "p.Pro301Ser",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:NEFM)",
      "concept": {
        "name": "NEFM",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "88a1411b9891a8f4be5d333c4a1aa113"
    },
    {
      "bel": "p(HGNC:NEFM, pmod(Ph))",
      "concept": {
        "name": "NEFM",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0b80a3f7bc9af58f404cad844f2280bd",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:NFE2L2)",
      "concept": {
        "name": "NFE2L2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7e8941fff5d3be67079854e55d40d075"
    },
    {
      "bel": "p(HGNC:NFE2L2, pmod(Ph))",
      "concept": {
        "name": "NFE2L2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5621ccb205aafee19ab68a464404c7e4",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Mitochondrial complex I assembly complex\")",
      "concept": {
        "name": "Mitochondrial complex I assembly complex",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "3efb8c0b634f6b79e30cf5c0bd8bac1d"
    },
    {
      "bel": "p(MESH:\"Neurofilament Proteins\")",
      "concept": {
        "name": "Neurofilament Proteins",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "a2e714494e6b0c8bf6dcfaaee8599d70"
    },
    {
      "bel": "p(MESH:\"Neurofilament Proteins\", pmod(Ph))",
      "concept": {
        "name": "Neurofilament Proteins",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "33a8be3eef0c74a07a67c212d6380f4f",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(UNIPROT:\"X5DSL3 (X5DSL3_ANAMA)\")",
      "concept": {
        "name": "X5DSL3 (X5DSL3_ANAMA)",
        "namespace": "UNIPROT"
      },
      "function": "Protein",
      "id": "860c1485017edc129c4f6736a3e8af46"
    },
    {
      "bel": "path(CONSO:\"4R tauopathy\")",
      "concept": {
        "name": "4R tauopathy",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "10e8fc6a039a64a8373232197d7a7b7f"
    },
    {
      "bel": "path(DOID:\"axonal neuropathy\")",
      "concept": {
        "name": "axonal neuropathy",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "586b835d2dd7f4d365386ebf14c115d6"
    },
    {
      "bel": "path(DOID:\"progressive supranuclear palsy\")",
      "concept": {
        "name": "progressive supranuclear palsy",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "5b66152a179940b80d4847ebf2938efa"
    },
    {
      "bel": "path(DOID:tauopathy)",
      "concept": {
        "name": "tauopathy",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "d7ea2ddee0e8e4835fed2018f7ccc042"
    },
    {
      "bel": "path(EFO:\"memory impairment\")",
      "concept": {
        "name": "memory impairment",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "7337e783dfeffa6227d5343c5f452a57"
    },
    {
      "bel": "path(MESH:\"Neuronal Plasticity\")",
      "concept": {
        "name": "Neuronal Plasticity",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "fb913e92f8f0adf0bbe67c0711ada06a"
    },
    {
      "bel": "path(MESH:\"Protein Conformation\")",
      "concept": {
        "name": "Protein Conformation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "5667656be06c32f484ebd15be830bd88"
    },
    {
      "bel": "path(MESH:Locomotion)",
      "concept": {
        "name": "Locomotion",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "e8e030bb909fd6ff614222cc88cbe869"
    },
    {
      "bel": "r(HGNC:HMOX1)",
      "concept": {
        "name": "HMOX1",
        "namespace": "HGNC"
      },
      "function": "RNA",
      "id": "d124041e4297a0905607cabab90a743b"
    },
    {
      "bel": "r(HGNC:SRSF2)",
      "concept": {
        "name": "SRSF2",
        "namespace": "HGNC"
      },
      "function": "RNA",
      "id": "d749a9e201c31088d3bd773ba8ede609"
    }
  ]
}